STOCK TITAN

Jasper Therapeutics (JSPR) awards 7,500 stock options to board director

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Jasper Therapeutics, Inc. reported that director Kurt Von Emster received a grant of stock options covering 7,500 shares of Voting Common Stock at an exercise price of $0.6300 per share. The options were granted automatically under the Non-Employee Director Compensation Policy, vest on July 31, 2027, and expire on July 31, 2036.

Positive

  • None.

Negative

  • None.
Insider EMSTER KURT VON
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy F1 7,500 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy — 7,500 shares (Direct)
Footnotes (1)
  1. F1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Stock options granted 7500.0000 options Grant to director Kurt Von Emster on July 31, 2026
Exercise price $0.6300 per share Exercise price for the granted stock options
Vesting date July 31, 2027 Options vest in full on the first anniversary of grant
Expiration date July 31, 2036 Reported expiration date for the granted options
Derivative holdings after grant 7500.0000 options Total stock options held after the reported transaction
Non-Employee Director Compensation Policy financial
"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy"
stock option financial
"non-employee directors are automatically granted an option to purchase 7,500 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"which shall vest in full upon the first anniversary of the date of the grant"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
conversion_or_exercise_price financial
"conversion_or_exercise_price of 0.6300 for the stock option grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock options were granted to Jasper Therapeutics (JSPR) director Kurt Von Emster?

Kurt Von Emster received a grant of stock options for 7,500 shares of Voting Common Stock. These were reported as a derivative award, increasing his post-transaction holdings to 7,500.0000 options linked to Jasper Therapeutics shares.

What is the exercise price of the new JSPR director stock options?

The granted options carry an exercise price of $0.6300 per share. This price applies to each of the 7,500 underlying shares of Voting Common Stock that may be purchased upon exercise of the options.

When do Kurt Von Emster's new Jasper Therapeutics (JSPR) options vest and expire?

The options are scheduled to vest in full on July 31, 2027, the first anniversary of the grant date. They are reported to expire on July 31, 2036, if not exercised earlier in accordance with their terms.

Under what policy were the JSPR director stock options granted?

The options were granted automatically under Jasper Therapeutics’ Non-Employee Director Compensation Policy. This policy provides that non-employee directors receive an option to purchase 7,500 shares on each annual meeting date, subject to service-based vesting.

Were the new JSPR director options granted under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked as a plan transaction. The grant instead arises automatically from the company’s Non-Employee Director Compensation Policy tied to the annual meeting of stockholders.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
EMSTER KURT VON

(Last)(First)(Middle)
C/O JASPER THERAPEUTICS, INC.
2200 BRIDGE PKWY, SUITE #102

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Jasper Therapeutics, Inc. [ JSPR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy$0.6307/31/2026A7,50007/31/2027(1)07/31/2036(1)Voting Common Stock7,500$0.007,500D
Explanation of Responses:
1. Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
/s/ Herb Cross, as Attorney-in-Fact08/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)